“Bimekizumab 4-year Maintenance of Responses in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-label Extension Phase 3 Trial”, J of Skin, vol. 8, no. 6, p. s437, Nov. 2024, doi: 10.25251/skin.8.supp.437.